Free Trial
NASDAQ:BCTX

Briacell Therap Q4 2024 Earnings Results & Report

Briacell Therap logo
$3.77 +0.08 (+2.17%)
Closing price 10/15/2026 03:51 PM Eastern
Extended Trading
$3.72 -0.04 (-1.19%)
As of 06:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Briacell Therap beat analyst earnings expectations in its Q4 2024 results, released October 28, 2024. The company reported EPS of -$10.50 versus the -$78.00 consensus estimate.

Earnings Announcement Details

Quarter
Q4 2024
Report Date
Time
TAS
Conference Call Date
Conference Call
8:00 AM ET

Briacell Therap EPS Results

Actual EPS
-$10.50
Consensus EPS
-$78.00
Beat/Miss
Beat by +$67.50
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Briacell Therap Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Earnings Documents

Briacell Therap Q4 2024 Earnings FAQ

Briacell Therap (NASDAQ:BCTX) reported earnings of -$10.50 per share for Q4 2024, beating the consensus estimate of -$78.00. The report was announced on Monday, October 28, 2024.

Briacell Therap Earnings Headlines

I'm giving you a space stock today. Free.
On December 8th, $600 billion in frozen SpaceX stock comes loose. Dylan Jovine says one simple purchase in any regular brokerage account gives investors exposure to SpaceX and 66 of its neighbors, without an IPO allocation. He is also naming two space stocks he would consider dumping before December, plus a $14 stock that Elon has personally put his name on.tc pixel
See More Briacell Therap Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Briacell Therap? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Briacell Therap and other key companies, straight to your email.

About Briacell Therap

Briacell Therap (NASDAQ:BCTX)eutics Corp. (NASDAQ: BCTX) is a clinical-stage biotechnology company developing targeted immunotherapies for cancer. The company focuses primarily on treatments for advanced breast cancer, with an emphasis on stimulating a patient’s immune system to recognize and attack tumor cells.

BriaCell’s lead product candidate is Bria-IMT, an immunotherapy derived from a breast cancer cell line and designed to activate cancer-fighting immune responses. The company has evaluated Bria-IMT in clinical studies for metastatic breast cancer, including in combination with immune checkpoint inhibitors. BriaCell is also developing Bria-OTS, an off-the-shelf immunotherapy platform intended to provide broader patient compatibility while supporting personalized cancer treatment approaches.

BriaCell Therapeutics is headquartered in Vancouver, British Columbia, and conducts its research and clinical development activities in North America. The company’s programs remain investigational and are subject to clinical and regulatory review. William Williams has served as the company’s president and chief executive officer.

View Briacell Therap Profile